Analysis of OHSU and TCGA (https://www.cbioportal.org/) data demonstrates the frequent presence of concurrent mutations in DNMT3A, FLT3, and TET2 genes in patients with AML. This evidence concerns the gene TET2 and acute myeloid leukemia.